Physician profile
Laura Badami
NPI 1386205961
$12,700.65
in general payments reported to CMS, 2019-2025
32 companies · $3,030 in 2025
The $3,030 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $1,125 · 2023: $3,610 · 2024: $4,676 · 2025: $3,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,791 · Consulting Fee: $850 · Education: $644 · Travel and Lodging: $30.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,790.76 |
| Consulting Fee | $850.00 |
| Education | $643.64 |
| Travel and Lodging | $30.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,215.17 | 2022-2025 | Tremfya |
| Abbvie INC. | $2,705.91 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $875.10 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $820.26 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $672.53 | 2022-2025 | |
| Dermavant Sciences, INC. | $578.91 | 2023-2024 | Vtama |
| Ucb, INC. | $496.49 | 2022-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $383.53 | 2022-2025 | Winlevi, Ilumya, Blu-U |
| Regeneron Healthcare Solutions, INC. | $349.37 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $344.03 | 2022-2025 | |
| Genzyme Corporation | $277.43 | 2022-2025 | |
| Galderma Laboratories, L.P. | $207.19 | 2024-2025 | Nemluvio |
| Incyte Corporation | $200.92 | 2022-2025 | Opzelura |
| Amgen INC. | $190.85 | 2022-2025 | Otezla |
| Organon LLC | $189.89 | 2023-2025 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $177.39 | 2023-2024 | Zoryve |
| Leo Pharma INC. | $146.75 | 2022-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $136.44 | 2022-2023 | |
| Glaxosmithkline, LLC. | $114.02 | 2021 | |
| Almirall LLC | $98.08 | 2023-2024 | Seysara |
| Astrazeneca Pharmaceuticals LP | $90.88 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $63.98 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.83 | 2023 | Cyltezo |
| Kyowa Kirin, INC. | $46.17 | 2021-2024 | Poteligeo |
| Biofrontera INC. | $43.42 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Kerecis Limited | $40.38 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.28 | 2023 | Arazlo |
| Revance Therapeutics, INC. | $20.55 | 2024 | Daxxify |
| Botanix Sb INC | $19.47 | 2025 | Sofdra |
| Genentech USA, INC. | $17.29 | 2023 | Xolair |
| Mylan Institutional INC. | $13.15 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Badami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.